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Introduction: Understanding factors affecting the time to recovery from acute mania is critical 
in the management of manic syndromes. The aim of this study was to determine the effect of 
HIV infection on time to recovery from acute mania.
Methods: We performed a retrospective study in which medical charts of individuals who were 
treated for acute mania were reviewed. Survival analysis with Cox regression models were used 
to compare time to recovery from an acute manic episode between human immunodeficiency 
virus (HIV)-positive individuals and HIV-negative individuals.
Results: Median survival time was one week for HIV-positive individuals and more than four 
weeks for HIV-negative individuals (χ2 = 18.4, P value = 0.000). HIV infection was the only 
marginally significant independent predictor of survival probability on the acute admission 
ward (hazards ratio 2.87, P = 0.06).
Conclusion: Acute mania in HIV-infected persons responds faster to psychotropic drugs 
compared with that in HIV-negative persons.
Keywords: HIV-related mania, bipolar disorder, HIV infection, Uganda, immunodeficiency 
virus
Introduction
In the past five years, an increasing body of evidence has accumulated describing the 
mental health problems of persons living with immunodeficiency virus (HIV)/acquired 
immunodeficiency syndrome (AIDS) in Uganda.1–5 These problems may be pre-existing 
mental illnesses in an individual who becomes secondarily infected with HIV or they 
may develop because of the direct or indirect effects of the HIV virus on the brain.6 
For example, we have previously described the clinical presentation of individuals with 
acute mania and HIV infection.7 Our research has shown that such individuals could 
have HIV-related secondary mania or bipolar disorder mania. HIV-positive individuals 
with bipolar disorder mania had more cognitive impairment, more immune suppres-
sion, more severe respiratory tract infections, and more current use of antituberculosis 
therapy compared with individuals with HIV-related secondary mania.7
Hospital data consistently show that bipolar disorder is the most common mental 
disorder seen at Butabika Hospital, Uganda’s only psychiatric hospital, accounting 
for 30%–35% of all first psychiatric hospitalizations annually. The prevalence of HIV 
infection among individuals with a first psychiatric hospitalization for severe mental 
disorder is estimated at 18%, which is three times the rate in the general population.8 
The literature on treatment outcomes of HIV-positive individuals with severe mental 
illness, such as bipolar disorder, is limited in low-resource settings like Uganda.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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In the context of HIV/AIDS, descriptive and treatment 
studies of acute mania in HIV-infected persons is lacking in 
developing countries. In developed countries, comprehensive 
reviews of the literature have provided compelling evidence 
that both typical and atypical antipsychotics are effective in 
the treatment of manic episodes in mentally ill, HIV-infected 
individuals.9–11 However, the literature on the effect of HIV 
infection in response to these treatments is limited. No study 
has compared the recovery time of HIV-positive individuals 
with acute mania with that of HIV-negative individuals with 
acute mania. Studies that we have performed comparing the 
clinical presentation of bipolar disorder mania versus that of 
HIV-related mania provided us with an opportunity to inves-
tigate the effect of HIV infection on time to recovery from an 
acute manic episode retrospectively. From our previous cross-
sectional studies, we had noted a quicker response to psycho-
tropic drugs among HIV-positive individuals compared with 
HIV-negative individuals with an acute manic episode.12
The aim of this study was to explore this finding further, 
using a survival analysis technique, and investigate its clini-
cal implications in the care of HIV-positive individuals in 
Uganda and other low-resource settings. We hypothesized 
that individuals with HIV infection would have a shorter 
time to recovery from an acute manic episode compared with 
those without HIV infection.
Material and methods
A random subsample of 60 medical charts were obtained from 
a sample of 155 medical charts of patients who, in 2004–2006, 
had participated in a previous study that described the clinical 
presentation of bipolar disorder mania in Butabika hospital.7 To 
obtain a random sample, we made a list of inpatient identifica-
tion numbers for patients who had participated in the previous 
study. Unique numbers 1–155 were assigned to each inpatient 
number. Pieces of paper labeled with these unique numbers 
were placed in a box and on each day of data collection, research 
assistants randomly picked 10 pieces of paper. The inpatient 
number corresponding with the number on the piece of paper 
was then used to trace the medical chart from the medical 
records office. Research assistants reviewed the medical charts 
and extracted data on variables of interest in this study. Medical 
charts that had incomplete data on variables of interest were 
excluded from the study. This process was repeated until we 
obtained a subsample of 60 medical charts.
These medical charts belonged to individuals aged 18 years 
and older, with a first episode of acute mania and without a 
history of substance or alcohol dependence. In addition, these 
study participants had not met the Diagnostic and Statistical 
Manual for Mental Disorders, Fourth edition (DSM-IV) 
criteria13 for delirium or a substance use disorder, and were 
not in the puerperium period. They had to have a laboratory 
record of their HIV serostatus, and a record of the dates of 
admission and discharge from the acute admission ward. In 
addition, study participants had to have sufficient data on other 
explanatory variables of interest including gender, age, years 
of education, source of referral, and treatment combination 
(whether patient was treated with an antipsychotic alone or 
in combination with a mood stabilizer or other drug).
The outcome of interest was time from psychotropic drug 
initiation (on the date of admission) to discharge from the acute 
admission ward. The decision to discharge a patient is made 
during major ward rounds that are conducted twice a week. The 
psychiatrist in charge of an acute admission ward, together with 
other members of the psychiatric team, carry out assessments 
based on DSM-IV criteria and make a decision as to whether 
a patient is fit for discharge or not. For acute mania, the deci-
sion to discharge an individual who was admitted with acute 
mania is based on the absence of all DSM-IV criteria for manic 
symptoms that were present at the time of admission. In this 
study, the “failure event” was considered as being discharge 
within four weeks of the date of admission. The Butabika 
Hospital Research Committee approved the study.
Statistical analysis
Statistical analysis was performed using Stata 10.0 (Stata 
Corp., College Station, TX).
Bivariate analyses were conducted to identify demographic 
and clinical variables that were significantly correlated with 
HIV-positive status at the time of admission. We used Chi-
square tests or Fisher’s Exact test for qualitative variables, and 
independent sample t-tests for continuous variables.
We computed Kaplan-Meier estimates and log-rank Chi-
square tests to determine the impact of study variables on 
survival in the acute admission wards. Study variables that 
were statistically significantly associated with HIV status 
and survival at P , 0.05 were entered into a Cox regression 
model to control for their effect when assessing the effect 
of HIV infection on time to recovery from an acute manic 
episode. We used graphical methods and Schoenfeld residuals 
to assess the proportional hazards assumption.
Results
There were 60 records selected for the study, but eight records 
did not have laboratory confirmation of HIV status, so were 
excluded from the data analysis. The majority of the study 
participants were HIV-positive (65.4%) and female (70%). HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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The mean age was 33.6 (standard deviation [SD] 6.9, range 
23–55) years. Sixty percent of the participants had more than 
eight years of formal education, indicating that they had at least 
attained secondary education level and above. Physicians and 
general practitioners had referred 34% of the study sample.
Among HIV-positive individuals, the mean CD4 count 
was 206 (SD 75.5, range 48–332). None of the HIV-positive 
individuals had initiated antiretroviral therapy prior to 
admission. Overall, 39 individuals with acute mania were 
discharged within four weeks of admission. The study par-
ticipants had a median time to recovery of 2.35 weeks (mean 
2.5, SD 1.59, range 3.5 days–5.0 weeks). Sixty percent of 
the study participants received monotherapy with one antip-
sychotic drug, either haloperidol or chlorpromazine. The 
relationship between the study variables and HIV infection 
among patients with acute mania is shown in Table 1.
Figures 1 and 2 show the Kaplan-Meier estimates of the 
survival distribution of time to discharge by HIV status and by 
mania status, respectively. Median survival time was one week 
for HIV-positive individuals and more than four weeks among 
HIV-negative individuals. These differences were statistically 
significant by the log-rank tests (χ2 = 18.4, P = 0.000 and 
χ2 = 33.6, P = 0.000, respectively). Individuals with HIV-related 
mania had the shortest median survival time of six days. Males 
had a median survival time of 3.7 weeks, whereas females had 
a survival time that averaged two weeks (log-rank test χ2 = 4.97, 
P = 0.03). Individuals over 30 years of age had a median sur-
vival time of 1.1 weeks whereas younger individuals had a 
survival time that averaged 2.7 weeks (log-rank test χ2 = 7.25, 
P = 0.007). Individuals referred from general hospitals and clin-
ics had a median survival of one week while those brought by 
relatives had a median survival time of 3.1 weeks (log-rank test 
χ2 = 7.11, P = 0.03). Individuals who had monotherapy with one 
antipsychotic drug had a median survival of one week, whereas 
those who had combination therapy with two antipsychotics or 
an antipsychotic and a mood stabilizer had a median survival 
time of 3.3 weeks (log-rank test χ2 = 11.5, P = 0.001).
Table 2 shows the Cox proportional hazard models for 
covariates with rate of discharge from acute admission wards. 
After controlling for study variables that were associated with 
both HIV and survival probability on the admission wards, 
HIV infection remained the only marginally significant 
independent predictor of survival probability on the acute 
admission wards (P = 0.06).
Discussion
HIV infection emerged as the only marginally significant 
independent predictor of survival time on the acute admission 
ward for individuals admitted with acute mania. Individuals 
with HIV-related mania had the shortest stay on the acute 
admission ward compared with those with bipolar mania 
regardless of HIV status. These findings strengthen previ-
ous theories that mania secondary to the pathophysiologic 
effects of the HIV virus on the brain may be different from 
bipolar mania in HIV-negative individuals.14,15 HIV-related 
mania appears to be more responsive to psychotropic drugs 
Table 1 The relationship between study variables and HIV infection among patients with acute mania
Characteristic HIV+ with mania N = 34% HIV- with mania N = 18% Odds ratio P-value
Age 
Less than 30 yrs
30 yrs & above
 
20.6 
79.4
 
79.4 
20.6
 
1 
13.5
 
 
,0.001
Gender 
Male 
Female
 
24 
76
 
44 
55
 
1 
2.6
 
 
0.125
Education years 
Less than 8 yrs 
8 yrs or more
 
56 
44
 
11 
89
 
1 
0.1
 
 
0.005
Employment 
Not employed 
employed
 
59 
41
 
17 
83
 
1 
0.14
 
 
0.006
Referral source 
Hospital/clinic 
Relatives 
Police
 
47 
26.5 
26.5
 
55.6 
16.7 
27.7
 
1 
0.12 
0.24
 
 
0.016 
0.128
Treatment  
Antipsychotic 
Antipsychotic & 
Mood stabilizer
 
79.4 
20.6
 
16.7 
83.3
 
1 
0.1
 
,0.001
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than mania in HIV-negative individuals. Previous studies 
have shown that HIV-related mania is responsive to both 
typical and atypical antipsychotics,16 –18 benzodiazepines 
such as clonazepam,19 and electroconvulsive therapy.20 
However, none of these studies compared responses to these 
psychotropic drugs between HIV-positive and HIV-negative 
individuals.
There are several limitations to our study. First, the 
study sample is small and thus may not have sufficient 
power to detect significant findings. Second, generalization 
0.00
0.25
0.50
0.75
1.00
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
0246
Length of stay on admission ward (weeks)
Acute mania & no HIV infection
Kaplan-Meier survival estimates
Acute mania & HIV infection
Figure 1 Kaplan-Meier estimates of the distribution of time until discharge from the admission wards (by HIV status) among individuals admitted with an acute episode of mania.
Abbreviation: HIV, human immunodeficiency virus.
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Figure 2 Kaplan-Meier estimates of the distribution of time until discharge from the admission wards (by mania status) among individuals admitted with an acute episode of mania.
Abbreviation: HIV, human immunodeficiency virus.HIV/AIDS - Research and Palliative Care
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of the findings to other HIV-positive populations is limited 
because this was a hospital-based study. Third, we could 
not control for nonadherence, critically ill status, or poor 
access to care. Finally, we did not have information on prior 
treatments given before referral to the psychiatric hospital 
that may have affected outcomes in this study.
Within the context of these limitations, this study 
points out important clinical implications for the care of 
HIV-positive individuals in Uganda. The rapid response 
to psychotropic drugs indicates that if prompt diagnosis 
of HIV-related manic symptoms is made, then treatment 
can be given in general medical settings. This will prevent 
affected individuals from progressing to severe manic states 
that may disrupt compliance with their treatment regimens. 
However, such evaluations can only be realized if providers 
of HIV care have adequate mental health communication 
skills. Comanagement of mental health problems should 
be an integrative part of HIV treatment and prevention 
programs.
We conclude that acute mania in HIV-infected persons 
responds faster to psychotropic drugs compared with 
responses in HIV-negative persons. Further prospective 
studies of treatment of mental health problems in HIV-
infected persons should be pursued aggressively to inform 
the holistic management of HIV-positive individuals in 
Uganda.
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Table 2 Cox proportional hazard regression models
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HIV infection 2.87 0.93–8.86 0.06
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8 or more education years 0.73 0.25–2.08 0.56
employed 0.86 0.39–1.92 0.72
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0.88 
2.23
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0.81 
0.12
Monotheraphy with  
antipsychotics
1.55 0.50–4.79 0.44
Abbreviations: HIV, human immunodeficiency virus; CI, confidence interval.